Results 131 to 140 of about 1,529,109 (298)

Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study

Journal of Comparative Effectiveness Research
Aim: Current Parkinson’s disease (PD) research evaluates patients with early and severe PD, but often overlooks patients with intermediate PD. This study aims to quantify unmet treatment needs, disease burden and healthcare resource utilization among ...
Malgorzata Ciepielewska, Eddie Jones, Alexander Gillespie, Chloe Walker, Laura LeBrocq, Sarah Weatherby   +5 more
doaj   +1 more source

QOL-21. REAL-WORLD QUALITY-OF-LIFE AND HEALTH UTILITIES FOR PATIENTS WITH CNS CANCERS ON THE XCELSIOR PLATFORM [PDF]

, 2022
Alanis Sabates, Alayna Wood, Hope Lee, Andrew Swain, Sabrina Irizarry, Chezney Hinton, Sarah Ginn, Zac Cole, Gordon Chavez, Kristina Tadic, Don Chuyka, Bryan Federowicz, Christina Proescholdt, Mark Shapiro   +13 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan

Journal of Asthma and Allergy
Hiroyuki Nagase,1 Urvee Karsanji,2 Hideaki Kunishige,3 Takeo Suzuki,4 Anna Vichiendilokkul,5 Liza Yuanita,6 Natsuki Sasakura,6 Jiaxuan Wang,7 Saeed Noibi8 1Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School
Nagase H, Karsanji U, Kunishige H, Suzuki T, Vichiendilokkul A, Yuanita L, Sasakura N, Wang J, Noibi S   +8 more
doaj  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Real World Data

Value in Health, 2007
openaire   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

OP0134 REAL WORLD “POLY-REFRACTORY RA”: A RARE BUT UNMET CLINICAL CHALLENGE [PDF]

, 2023
David Pubill, Andrea Di Matteo, Or Hen, S. Dass, Paul Emery, Benazir Saleem, Dennis McGonagle   +6 more
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

#277 Systemic therapy and outcomes in metastatic/recurrent endometrial cancer – real world population study [PDF]

, 2023
Agnes Ho, Anu Chinnadurai, Alexandra N. Lemanowicz, Longlong Huang, Shaun Zheng Sun, Jenny J. Ko   +5 more
openalex   +1 more source